Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

NCT04231864 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Feasibility

Conditions

Epstein-Barr Virus Positive
Metastatic Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Stage III Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma
Stage IVA Nasopharyngeal Carcinoma
Stage IVB Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL: Durvalumab
DRUG: Epacadostat

Sponsor

Alain Algazi

Collaborators

[object Object]
[object Object]